Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592739 | SCV000707651 | uncertain significance | not provided | 2018-03-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483640 | SCV002781992 | uncertain significance | Polycystic kidney disease 4 | 2024-06-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002532582 | SCV003594143 | uncertain significance | Inborn genetic diseases | 2021-12-03 | criteria provided, single submitter | clinical testing | The c.10940A>C (p.H3647P) alteration is located in exon 61 (coding exon 60) of the PKHD1 gene. This alteration results from a A to C substitution at nucleotide position 10940, causing the histidine (H) at amino acid position 3647 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000592739 | SCV005189042 | uncertain significance | not provided | criteria provided, single submitter | not provided |